A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration

Trial Profile

A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2017

At a glance

  • Drugs RXI 109 (Primary)
  • Indications Scars; Wet age-related macular degeneration
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors RXi Pharmaceuticals
  • Most Recent Events

    • 21 Jun 2017 According to a RXi Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
    • 13 Apr 2017 Results from this trial are expected in 2018, according to an RXi Pharmaceuticals media release.
    • 13 Dec 2016 According to a RXi Pharmaceuticals media release, complete enrolment is anticipated for early in 2017, with a complete safety read out of the study in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top